<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contralateral prophylactic mastectomy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contralateral prophylactic mastectomy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Contralateral prophylactic mastectomy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell S Berman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21364200"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with a unilateral sporadic breast cancer are at a modest risk of developing an invasive contralateral breast cancer (CBC). While most women never will develop a contralateral second primary breast cancer, risk-reducing strategies may be appropriate for some. A contralateral prophylactic mastectomy (CPM) is a risk-reducing mastectomy performed in the clinical setting for the patient diagnosed with an invasive or a noninvasive breast cancer. While there is no clear survival benefit for most breast cancer patients who do not carry a deleterious breast cancer susceptibility gene 1 or 2 (<em>BRCA1</em> or <em>BRCA2</em>) mutation [<a href="#rid1">1-3</a>], the rates of performing a CPM have increased over the last several years [<a href="#rid4">4,5</a>].</p><p>The risk of a contralateral breast cancer, the decision-making process to undergo a CPM, and outcomes will be reviewed in this topic. Management of patients with invasive and noninvasive breast cancer, with and without an inherited genetic mutation, is reviewed separately. Medical therapy for breast cancer risk reduction is also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/756.html" rel="external">"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention"</a>.)</p><p></p><p class="headingAnchor" id="H2296582"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The rationale for CPM in a patient who has had breast cancer is to reduce the risk of contralateral breast cancer. </p><p>Risk of contralateral breast cancer among breast cancer patients is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who present with unilateral breast cancer, the risk of developing a contralateral breast cancer is estimated to be 0.4 to 1.0 percent per year cumulative over their lifetime [<a href="#rid6">6-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with breast cancer who carry a deleterious breast cancer susceptibility gene 1 or 2 (<em>BRCA1</em> or <em>BRCA2</em>) mutation, the risk of a contralateral breast cancer is approximately 10 to 25 percent [<a href="#rid11">11,12</a>]. However, some studies have estimated the risk to be as high as 65 percent for <em>BRCA1</em> carriers and 50 percent for <em>BRCA2</em> carriers [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes", section on 'Breast cancer risk management'</a>.)</p><p></p><p>Other reasons for undergoing a CPM include relative ease of follow-up without a mammogram or magnetic resonance imaging (MRI), reduction of anxiety for occurrence of a second breast cancer, and desire for symmetry that can be achieved with bilateral mastectomies and reconstruction.</p><p class="headingAnchor" id="H21364213"><span class="h1">CANDIDATE SELECTION</span><span class="headingEndMark"> — </span>Risk-reduction prophylactic mastectomy is often offered to patients with or without a previous history of breast cancer who carry a germline genetic mutation conferring a high risk for breast cancer (breast cancer susceptibility genes 1 and 2 [<em>BRCA1/2</em>], tumor protein p53 [<em>TP53</em>], phosphatase and tensin homolog [<em>PTEN</em>], cadherin 1 [<em>CDH1</em>], or serine/threonine protein kinase 11 [<em>STK11</em>] mutation), those with a strong family history of breast or ovarian cancer, and those with a history of thoracic radiation therapy at &lt;30 years of age [<a href="#rid14">14</a>]. This approach is consistent with guidelines from the National Comprehensive Cancer Network. For those specifically who have had breast cancer, the decision for CPM takes into account many of the same factors that go into decisions about prophylactic mastectomy. However, the decision to undergo a CPM is frequently an individual patient’s choice and based on the management (eg, mastectomy) of the presenting breast cancer, the risk of contralateral disease given an ipsilateral cancer, their desire for symmetry, and anxieties regarding follow-up imaging. Family history, genetics, and other markers of increased risk may weigh on a patient’s decision regarding CPM.</p><p>Some subsets of patients may also be at high risk of epithelial ovarian and fallopian tube cancer and would benefit from risk-reducing bilateral salpingo-oophorectomy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer", section on 'Candidates'</a>.)</p><p>While, previously, women with lobular carcinoma in situ were thought to be at significant risk such that bilateral prophylactic mastectomy was offered, a more preferable approach for such patients is risk-reducing medical therapy. (See  <a class="medical medical_review" href="/z/d/html/743.html" rel="external">"Atypia and lobular carcinoma in situ: High-risk lesions of the breast"</a>.)</p><p class="headingAnchor" id="H1394855091"><span class="h1">DECISION-MAKING PROCESS</span><span class="headingEndMark"> — </span>The decision to undergo a CPM is generally based upon the patient's personal preference as well as the surgical management of the presenting breast cancer (ie, mastectomy). Patients often state that their decision may be (in part) influenced by other people, including the surgeon, primary care clinician, friends, and/or family members. Hence, the patient and her surgeon should fully discuss the actual risks of a contralateral breast cancer in terms of the patient’s own personal and family history and her goals for treatment. (See <a class="local">'Pretreatment counseling'</a> below.)</p><p class="headingAnchor" id="H3437385472"><span class="h2">Pretreatment counseling</span><span class="headingEndMark"> — </span>The frequency of CPM has increased from nearly 4 percent in 2002 to almost 13 percent in 2012, despite a lack of survival benefit associated with the procedure [<a href="#rid15">15</a>]. It must also be recognized, however, that data involving CPM is not based on randomized trials, thus limiting our knowledge about potential improvements in survival. Providers should engage in a discussion with patients considering CPM regarding limitations in the data, the patient’s perceived versus the actual benefits of the procedure, and the accompanying risks. The likelihood of contralateral breast cancer should also be discussed. (See <a class="local">'Rationale'</a> above.)</p><p>Regarding potential benefits, evidence shows that the risk of contralateral breast cancer is reduced by CPM, and this may be sufficient rationale for some women at risk of a second breast cancer to pursue the procedure. However, it has been shown that the average woman overestimates her risk of contralateral breast cancer at the time of her initial breast cancer diagnosis [<a href="#rid16">16</a>]. Providers must therefore ensure patients have accurate data regarding their baseline level of risk as they make the decision regarding CPM. Furthermore, although many women opt for CPM in order to improve and extend life, available data, although limited, have shown a survival benefit only for those who carry deleterious breast cancer susceptibility gene 1 or 2 (<em>BRCA1 </em>or<em> BRCA2</em>) mutations [<a href="#rid2">2,17</a>]. Most women undergoing CPM, however, do not have such mutations or a strong family history [<a href="#rid18">18</a>]. Patients must also be made aware of the risks and complications of undergoing a CPM, as this involves a more extensive operation (bilateral mastectomies with or without bilateral reconstruction). (See <a class="local">'Outcomes'</a> below.)</p><p>Despite knowing that CPM does not clearly improve survival, women who have the procedure do so, in part, to extend their lives. Based upon a survey of 123 women with unilateral breast cancer, most women who undergo a CPM do so with a desire to reduce the risk of a contralateral breast cancer (98 percent) and improve survival (94 percent) [<a href="#rid19">19</a>]. However, only 18 percent believed that women undergoing a CPM lived longer. These discordant findings suggest that cognitive dissonance exists in decision-making. Although women understand that a CPM is unlikely to extend their survival, anxiety and fear of recurrence may be driving their decisions. Interventions aimed at improving risk communication in an effort to promote evidence-based decision making are warranted.</p><p class="headingAnchor" id="H19678549"><span class="h2">Factors influencing patient choice</span><span class="headingEndMark"> — </span>A number of sociodemographic and tumor characteristics have been associated with a higher likelihood of pursuing CPM, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age [<a href="#rid4">4,6,20-23</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Being from a White population [<a href="#rid4">4,21,22</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Private health insurance [<a href="#rid21">21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of breast cancer [<a href="#rid4">4,20,22-24</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Noninvasive histology [<a href="#rid4">4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Lobular tumor histology [<a href="#rid22">22,23,25</a>]</p><p></p><p>Other factors, such as preoperative evaluation with a bilateral breast magnetic resonance imaging (MRI) [<a href="#rid4">4,24</a>], failed attempt at breast conservation management [<a href="#rid4">4</a>], and the option of immediate reconstruction [<a href="#rid4">4,22,24</a>], are independently associated with the decision to pursue CPM.</p><p class="headingAnchor" id="H21364239"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H2473936451"><span class="h2">Breast cancer risk reduction</span><span class="headingEndMark"> — </span>The risks of a contralateral breast cancer in a woman with a personal history of breast cancer are about 4 percent over 10 years [<a href="#rid26">26</a>]. Family history affects this incidence. These data are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women", section on 'Personal and family history of breast cancer'</a> and  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women", section on 'Medical and surgical risk reduction strategies'</a>.)</p><p>In a Cochrane meta-analysis including 26 observational studies of contralateral risk-reducing mastectomy, risk of contralateral breast cancer was reduced consistently across the studies, but studies were inconsistent in regards to whether disease-specific survival was improved [<a href="#rid27">27</a>].</p><p>Benefits for CPM are likely higher for younger women. Based upon a prospective study of 745 women with breast cancer and a family history of breast and/or ovarian cancer undergoing a CPM, the risk reduction of a contralateral breast cancer (CBC) was approximately 96 percent [<a href="#rid6">6</a>]. In this cohort, the risk reduction following a CPM for women less than age 50 years was 94.4 percent (n = 388; number needed to treat [NNT] 3.6), and 96.0 percent for women 50 years of age and older (n = 357; NNT 7.4).</p><p>The likelihood of finding an occult invasive or noninvasive breast cancer in the CPM specimen, not identified on radiographic imaging (ie, mammogram, magnetic resonance imaging [MRI]), is low and reported to be approximately 1 to 2 percent [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H89077829"><span class="h2">Overall survival</span><span class="headingEndMark"> — </span>Retrospective and observational data have not suggested an overall survival benefit for most breast cancer patients who undergo a CPM [<a href="#rid15">15,30,31</a>], though prospective randomized data are lacking. However, for patients with a deleterious breast cancer susceptibility gene 1 or 2 (<em>BRCA1</em> or <em>BRCA2</em>) mutation, and in some studies, women diagnosed at a young age (&lt;50 years), a survival benefit has been attributed to a CPM [<a href="#rid1">1,2,5,17,32</a>]. (See <a class="local">'BRCA carriers'</a> below.)</p><p>In a study of almost 500,000 women with unilateral stage I to III breast cancer enrolled in the Surveillance, Epidemiology, and End Results database, there was no improvement with CPM in either breast cancer-specific survival (hazard ratio [HR] 1.08, 95% CI 1.01-1.16) or overall survival (HR 1.08, 95% CI 1.03-1.14) compared with breast-conserving therapy alone [<a href="#rid15">15</a>]. Similarly, in a propensity matched analysis of almost 190,000 patients with stage 0 to III breast cancer in the California Cancer Registry, there was no significant mortality difference between those undergoing breast-conserving therapy or bilateral mastectomy (though both were associated with lower mortality than unilateral mastectomy) [<a href="#rid30">30</a>].</p><p>Results among younger women, however, are mixed [<a href="#rid1">1,31,33</a>]. For example, in a study of almost 15,000 women aged ≤45 years with stage I or II breast cancer, those receiving CPM and unilateral mastectomy versus unilateral mastectomy alone experienced no survival benefit [<a href="#rid31">31</a>]. By contrast, in an earlier risk-stratified analysis of almost 9000 women with early breast cancer enrolled in the Surveillance, Epidemiology, and End Results (SEER) database, CPM was associated with improved disease-specific survival (0.63, 95% CI 0.57-0.69), an effect that was due to improvements in breast cancer-specific mortality among patients ages 18 to 49 years with stage I to II estrogen receptor (ER)-negative breast cancer [<a href="#rid1">1</a>]. Five-year adjusted breast cancer survival for such patients was improved with CPM versus without (89 versus 84 percent).</p><p>For women with breast cancer who carry a deleterious <em>BRCA1/2</em> mutation, a CPM can improve breast cancer survival [<a href="#rid3">3,34</a>]. (See <a class="local">'BRCA carriers'</a> below.)</p><p class="headingAnchor" id="H2591877051"><span class="h2">Risks</span></p><p class="headingAnchor" id="H1933768585"><span class="h3">Postoperative morbidity and mortality</span><span class="headingEndMark"> — </span>Mortality rates are uniformly low (&lt;1 percent) in patients undergoing an elective mastectomy [<a href="#rid35">35,36</a>]. However, morbidity associated with CPM occurs in one in eight women [<a href="#rid37">37</a>]. The complications of a mastectomy include seroma, surgical site infection (SSI), skin flap necrosis, nipple necrosis, postoperative pain, postmastectomy pain syndrome, phantom breast syndrome, arm mobility limitations, pneumothorax, brachial plexopathy, and the risks of an anesthetic and reconstruction, if performed. These complications are discussed separately elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14981.html" rel="external">"Mastectomy", section on 'Complications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14973.html" rel="external">"Clinical manifestations and diagnosis of postmastectomy pain syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86609.html" rel="external">"Postmastectomy pain syndrome: Risk reduction and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14946.html" rel="external">"Overview of post-anesthetic care for adult patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/801.html" rel="external">"Overview of breast reconstruction"</a>.)</p><p></p><p>The frequency of complications following a bilateral mastectomy is greater than a unilateral mastectomy. For example, in one study of 352 women who underwent bilateral or unilateral mastectomy for breast cancer, more women undergoing bilateral mastectomy experienced complications (31 versus 23 percent), of which hematoma, skin necrosis, cellulitis, or seroma accounted for 84 percent of cases [<a href="#rid37">37</a>]. Of those undergoing bilateral mastectomy, morbidity occurred only in the prophylactic breast in 13 percent of cases, with half of these requiring reoperation. By contrast, in a separate study in 471 patients, contralateral prophylactic mastectomy was not associated with a greater 90-day reoperation rate for complications (although it was associated with increased hospital stays) [<a href="#rid38">38</a>].</p><p>Similarly, another retrospective review of the American College of Surgeons National Surgery Quality Improvement Program (ACS NSQIP) database of 4219 breast cancer patients between 2007 and 2010 found a higher rate of SSI in patients undergoing a CPM compared with a unilateral mastectomy (5.8 versus 2.9 percent) [<a href="#rid39">39</a>]. The 30-day complication rate following a CPM was significantly higher (7.6 versus 4.2 percent), even when adjusted for body mass index and smoking history (odds ratio [OR] 1.9, 95% CI 1.3-2.8).</p><p class="headingAnchor" id="H89078687"><span class="h3">Psychosocial effects</span></p><p class="headingAnchor" id="H7111097"><span class="h4">Body image, femininity</span><span class="headingEndMark"> — </span>Adverse changes in body image including diminished feelings of femininity, sexuality and sexual satisfaction, and self-esteem can occur following a CPM [<a href="#rid6">6,40-43</a>]. Negative body image was also associated with high preoperative cancer distress [<a href="#rid40">40</a>]. In a survey of women who had undergone CPM, 42 percent stated that their sense of sexuality was worse than expected, and 31 percent felt that their self-consciousness about their appearance was also worse than expected [<a href="#rid19">19</a>]. However, 80 percent reported that they were "extremely confident in their decision to have CPM", and 90 percent would have made the same decision again [<a href="#rid19">19</a>]. </p><p>The personal satisfaction following a CPM is reportedly high [<a href="#rid43">43,44</a>]. For example, a survey of 583 patients found that the majority (83 percent) of women were satisfied with the CPM 10 years after the operation, while 8 percent were neutral and 9 percent were dissatisfied [<a href="#rid43">43</a>]. However, 33 percent were dissatisfied with body appearance, 26 percent had adverse feelings of femininity, and 23 percent reported adverse sexual relationships. </p><p>Such a high level of satisfaction may be secondary to cognitive dissonance, a phenomenon documented in validated patient satisfaction measurements, and relevant to autonomous surgical decision-making when the decision is difficult to change [<a href="#rid2">2,45-47</a>]. </p><p class="headingAnchor" id="H89078829"><span class="h4">Quality of life</span><span class="headingEndMark"> — </span>Quality-of-life-related measures for women undergoing a CPM were comparable to women in the general population. In a prospective study of 60 women with breast cancer who had also undergone a CPM, most patients had a satisfactory health-related quality of life two years after the operation, with no difference in anxiety or depression [<a href="#rid42">42</a>]. </p><p>In the meta-analysis discussed above, studies reported reduced anxiety regarding breast cancer relative to those who opted for surveillance [<a href="#rid2">2</a>]. (See <a class="local">'Overall survival'</a> above.)</p><p class="headingAnchor" id="H89079098"><span class="h1">OPERATIVE APPROACHES</span></p><p class="headingAnchor" id="H17828615"><span class="h2">Mastectomy with or without reconstruction</span><span class="headingEndMark"> — </span>Typically, most patients are advised to undergo the same type of mastectomy (eg, skin-sparing, conventional) that is used for the mastectomy to treat the breast cancer. For women with mutations in breast cancer susceptibility gene 1 or 2 (<em>BRCA1</em>/<em>2</em>) or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach [<a href="#rid48">48</a>]. The type of mastectomy is determined by the tumor characteristics, patient body habitus, patient preference, and surgical expertise. There is no adverse impact of immediate reconstruction either in the development or detection of future cancers [<a href="#rid49">49</a>]. Reconstruction is determined by the use of postoperative radiation treatments, patient preference, and surgeon expertise.</p><p>Specific approaches to performing a mastectomy and breast reconstruction are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14981.html" rel="external">"Mastectomy"</a> and  <a class="medical medical_review" href="/z/d/html/801.html" rel="external">"Overview of breast reconstruction"</a>.)</p><p class="headingAnchor" id="H89079053"><span class="h2">Sentinel lymph node dissection</span><span class="headingEndMark"> — </span>While there are differences of opinion, a sentinel lymph node dissection is not required when performing a CPM [<a href="#rid28">28,29,50</a>]. Some have argued that the risk of this minimally invasive procedure is small, and would preempt the need for axillary evaluation if an occult invasive cancer was found on final pathology [<a href="#rid50">50</a>]. Others, however, argue that the risk of finding metastatic disease warranting axillary staging in patients undergoing prophylactic mastectomy is low, and therefore sentinel node biopsy in these patients can be omitted [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/805.html" rel="external">"Sentinel lymph node biopsy in breast cancer: Techniques"</a>.)</p><p class="headingAnchor" id="H3609445252"><span class="h1">OTHER ASPECTS OF RISK REDUCTION</span><span class="headingEndMark"> — </span>Most women with early breast cancer will be offered some type of adjuvant systemic therapy, the exception being possibly for those with very small "triple-negative" tumors (&lt;0.5 cm). Systemic therapy may consist of chemotherapy, depending on the stage of the cancer and other prognostic and predictive features, human epidermal growth factor receptor 2 (HER2)-directed therapy for HER2-positive tumors, and endocrine therapy for hormone receptor-positive tumors. The decision to proceed with CPM does not affect these recommendations. For those with hormone receptor-positive, invasive tumors, adjuvant endocrine therapy has been shown to reduce the risk of breast cancer recurrence. Discussion of appropriate adjuvant therapy as well as medical risk-reducing strategies is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/756.html" rel="external">"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention"</a>.)</p><p>For those who do not proceed with CPM, breast cancer surveillance remains an important aspect of risk management. (See  <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">"Approach to the patient following treatment for breast cancer", section on 'Breast imaging'</a>.)</p><p class="headingAnchor" id="H2169051514"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H4171112891"><span class="h2">BRCA carriers</span><span class="headingEndMark"> — </span>Breast cancer susceptibility gene 1 and 2 (<em>BRCA1 AND BRCA2 </em>[<em>BRCA</em>]) mutation carriers have a consistently documented increased risk of ipsilateral and contralateral breast cancer [<a href="#rid12">12</a>]. Therefore, even though breast conservation therapy appears to be an effective local treatment option in these patients [<a href="#rid11">11,12,51,52</a>], they may opt to undergo bilateral mastectomy to reduce their risk of a second breast cancer. CPM is an effective and popular option for reducing the risk of contralateral breast cancer recurrence, and evidence suggests that it may improve disease-free and overall survival [<a href="#rid1">1,2,7,12,53,54</a>]. It is important to note, however, that the absolute risk of contralateral breast cancer in mutation carriers diminishes significantly if their first breast cancer is diagnosed after age 50 [<a href="#rid13">13</a>].</p><p>The following studies illustrate the benefits of CPM among <em>BRCA</em> carriers with breast cancer:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of 181 patients, a CPM was associated with a 48 percent reduction in death from breast cancer (hazard ratio [HR] 0.52, 95% CI 0.29-0.93) [<a href="#rid3">3</a>]. The 20-year survival rate for <em>BRCA</em> carriers undergoing a CPM was 88 percent compared with a 66 percent survival rate for carriers treated with a unilateral mastectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review and matched analysis of 105 women with breast cancer and a deleterious <em>BRCA</em> mutation undergoing a CPM had a greater ten-year survival compared with <em>BRCA</em> carriers with breast cancer who did not undergo a CPM (n = 593; 89 versus 71 percent) [<a href="#rid34">34</a>]. After adjusting for potential confounders, such as oophorectomy, grade and stage of cancer, and specific gene with the mutation, CPM continued to provide a survival advantage (HR 0.37, 95% CI 0.17-0.80).</p><p></p><p class="headingAnchor" id="H740299651"><span class="h2">Considerations during the COVID-19 pandemic</span><span class="headingEndMark"> — </span>The COVID-19 pandemic has increased the complexity of cancer care. Important issues in areas where viral transmission rates are high include balancing the risk from treatment delay versus harm from COVID-19, ways to minimize negative impacts of social distancing during care delivery, and appropriately and fairly allocating limited health care resources. These and other recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H4016860282"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119888.html" rel="external">"Society guideline links: Hereditary breast and ovarian cancer"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H89079164"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Patients with a unilateral sporadic breast cancer are at a modest risk of developing an invasive contralateral breast cancer (CBC), and most women never will develop a contralateral second primary breast cancer. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – The rationale for contralateral prophylactic mastectomy (CPM) in a patient who has had breast cancer is to reduce the risk of CBC. Other reasons for undergoing a CPM include relative ease of follow-up without a mammogram or magnetic resonance imaging (MRI), reduction of anxiety for occurrence of a second breast cancer, and desire for symmetry that can be achieved with bilateral mastectomies and reconstruction. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidate selection</strong> – Risk-reduction mastectomy is often offered to patients with or without a previous history of breast cancer who carry a germline genetic mutation conferring a high risk for breast cancer (breast cancer susceptibility genes 1 and 2 [<em>BRCA1/2</em>], tumor protein p53 [<em>TP53</em>], phosphatase and tensin homolog [<em>PTEN</em>], cadherin 1 [<em>CDH1],</em> or serine/threonine protein kinase 11 [<em>STK11</em>] mutation), those with a strong family history of breast or ovarian cancer, and those with a history of thoracic radiation therapy at &lt;30 years of age. </p><p></p><p class="bulletIndent1">The decision to undergo a CPM is based on these same factors but is also individualized according to patient preferences and history, taking into account the surgical management of the presenting breast cancer (ie, mastectomy), the risk of contralateral disease given an ipsilateral cancer, and the patient’s desire for symmetry and anxieties regarding follow-up imaging. (See <a class="local">'Candidate selection'</a> above and <a class="local">'Decision-making process'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer risk reduction</strong> – Women with breast cancer and a family history of breast or ovarian cancer and who undergo a CPM have a 96 percent reduction in risk of developing a contralateral cancer. (See <a class="local">'Breast cancer risk reduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect on overall survival</strong> – There is no clear overall survival benefit for most breast cancer patients who undergo a CPM, though prospective randomized data are unavailable. However, a survival benefit with CPM exists for patients with a deleterious <em>BRCA1</em> or <em>BRCA2</em> mutation, and possibly for those diagnosed at a young age (&lt;50 years). (See <a class="local">'Overall survival'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Women with breast cancer undergoing a CPM have nearly a twofold increased risk of major complications (eg, reoperation) compared with women undergoing a unilateral mastectomy. (See <a class="local">'Postoperative morbidity and mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Operative approaches</strong> – Typically, the same type of mastectomy is performed for a CPM as for the mastectomy to treat the breast cancer. (See <a class="local">'Mastectomy with or without reconstruction'</a> above and  <a class="medical medical_review" href="/z/d/html/14981.html" rel="external">"Mastectomy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010; 102:401.</a></li><li><a class="nounderline abstract_t">Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; :CD002748.</a></li><li><a class="nounderline abstract_t">Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014; 348:g226.</a></li><li><a class="nounderline abstract_t">King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011; 29:2158.</a></li><li><a class="nounderline abstract_t">Zeichner SB, Zeichner SB, Ruiz AL, et al. Improved long-term survival with contralateral prophylactic mastectomy among young women. Asian Pac J Cancer Prev 2014; 15:1155.</a></li><li><a class="nounderline abstract_t">McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001; 19:3938.</a></li><li><a class="nounderline abstract_t">Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005; 23:4275.</a></li><li><a class="nounderline abstract_t">Schell SR, Montague ED, Spanos WJ Jr, et al. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982; 50:1191.</a></li><li><a class="nounderline abstract_t">Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984; 71:711.</a></li><li><a class="nounderline abstract_t">Giannakeas V, Lim DW, Narod SA. The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 2021; 125:601.</a></li><li><a class="nounderline abstract_t">Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009; 16:3380.</a></li><li><a class="nounderline abstract_t">Trainer AH, Lewis CR, Tucker K, et al. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010; 7:708.</a></li><li><a class="nounderline abstract_t">Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27:5887.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast cancer risk reduction. https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf (Accessed on February 16, 2017).</li><li><a class="nounderline abstract_t">Wong SM, Freedman RA, Sagara Y, et al. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg 2017; 265:581.</a></li><li><a class="nounderline abstract_t">Abbott A, Rueth N, Pappas-Varco S, et al. Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 2011; 18:3129.</a></li><li><a class="nounderline abstract_t">van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93:287.</a></li><li><a class="nounderline abstract_t">Rosenberg SM, Sepucha K, Ruddy KJ, et al. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Ann Surg Oncol 2015; 22:3809.</a></li><li><a class="nounderline abstract_t">Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med 2013; 159:373.</a></li><li><a class="nounderline abstract_t">Güth U, Myrick ME, Viehl CT, et al. Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol 2012; 38:296.</a></li><li><a class="nounderline abstract_t">Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol 2010; 17:2554.</a></li><li><a class="nounderline abstract_t">Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 2010; 3:1026.</a></li><li><a class="nounderline abstract_t">Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 2009; 16:2697.</a></li><li><a class="nounderline abstract_t">Chung A, Huynh K, Lawrence C, et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 2012; 19:2600.</a></li><li><a class="nounderline abstract_t">Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381.</a></li><li><a class="nounderline abstract_t">Reiner AS, Sisti J, John EM, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 2018; 36:1513.</a></li><li><a class="nounderline abstract_t">Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 2018; 4:CD002748.</a></li><li><a class="nounderline abstract_t">Murthy V, Chamberlain RS. Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy? Clin Breast Cancer 2013; 13:180.</a></li><li><a class="nounderline abstract_t">Nasser SM, Smith SG, Chagpar AB. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. J Surg Res 2010; 164:188.</a></li><li><a class="nounderline abstract_t">Kurian AW, Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 2014; 312:902.</a></li><li><a class="nounderline abstract_t">Pesce C, Liederbach E, Wang C, et al. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol 2014; 21:3231.</a></li><li><a class="nounderline abstract_t">Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014; 260:1000.</a></li><li><a class="nounderline abstract_t">Donovan CA, Bao J, Gangi A, et al. Bilateral Mastectomy as Overtreatment for Breast Cancer in Women Age Forty Years and Younger with Unilateral Operable Invasive Breast Cancer. Ann Surg Oncol 2017; 24:2168.</a></li><li><a class="nounderline abstract_t">Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2013; 140:135.</a></li><li><a class="nounderline abstract_t">El-Tamer MB, Ward BM, Schifftner T, et al. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 2007; 245:665.</a></li><li><a class="nounderline abstract_t">Hynes DM, Weaver F, Morrow M, et al. Breast cancer surgery trends and outcomes: results from a National Department of Veterans Affairs study. J Am Coll Surg 2004; 198:707.</a></li><li><a class="nounderline abstract_t">Eck DL, Perdikis G, Rawal B, et al. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol 2014; 21:3297.</a></li><li><a class="nounderline abstract_t">Huang J, Chagpar A. Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy. Surgery 2018; 164:1347.</a></li><li><a class="nounderline abstract_t">Osman F, Saleh F, Jackson TD, et al. Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database. Ann Surg Oncol 2013; 20:3212.</a></li><li><a class="nounderline abstract_t">Gopie JP, Mureau MA, Seynaeve C, et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Fam Cancer 2013; 12:479.</a></li><li><a class="nounderline abstract_t">Brandberg Y, Sandelin K, Erikson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 2008; 26:3943.</a></li><li><a class="nounderline abstract_t">Unukovych D, Sandelin K, Liljegren A, et al. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer 2012; 48:3150.</a></li><li><a class="nounderline abstract_t">Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005; 23:7849.</a></li><li><a class="nounderline abstract_t">Han E, Johnson N, Glissmeyer M, et al. Increasing incidence of bilateral mastectomies: the patient perspective. Am J Surg 2011; 201:615.</a></li><li><a class="nounderline abstract_t">Carr-Hill RA. The measurement of patient satisfaction. J Public Health Med 1992; 14:236.</a></li><li><a class="nounderline abstract_t">Homer JJ, Sheard CE, Jones NS. Cognitive dissonance, the placebo effect and the evaluation of surgical results. Clin Otolaryngol Allied Sci 2000; 25:195.</a></li><li><a class="nounderline abstract_t">van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003; 21:3867.</a></li><li><a class="nounderline abstract_t">Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 2020; 38:2080.</a></li><li><a class="nounderline abstract_t">Chagpar AB. Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative, and postoperative considerations. Am Surg 2004; 70:425.</a></li><li><a class="nounderline abstract_t">Burger A, Thurtle D, Owen S, et al. Sentinel lymph node biopsy for risk-reducing mastectomy. Breast J 2013; 19:529.</a></li><li><a class="nounderline abstract_t">Robson M, Svahn T, McCormick B, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005; 103:44.</a></li><li><a class="nounderline abstract_t">Chabner E, Nixon A, Gelman R, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998; 16:2045.</a></li><li><a class="nounderline abstract_t">Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26:1093.</a></li><li><a class="nounderline abstract_t">Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010; 17:2702.</a></li></ol></div><div id="topicVersionRevision">Topic 94744 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185801" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069671" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prophylactic mastectomy for the prevention of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24519767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464413" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606434" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Improved long-term survival with contralateral prophylactic mastectomy among young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579114" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15795415" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104963" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bilateral breast cancer in patients with initial stage I and II disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6478165" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bilateral primary breast cancer: a prospective study of disease incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34040177" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The risk of contralateral breast cancer: a SEER-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19649554" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060331" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The role of BRCA mutation testing in determining breast cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858402" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858402" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169929" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947590" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Perceptions of contralateral breast cancer: an overestimation of risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16052221" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25930247" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24042365" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305274" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increasing rates of contralateral prophylactic mastectomy - a trend made in USA?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20461470" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647335" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19653045" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396004" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21639806" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Exemestane for breast-cancer prevention in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620998" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620792" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk-reducing mastectomy for the prevention of primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23357305" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20869074" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of sentinel node biopsy in women undergoing prophylactic mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25182099" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081341" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24950272" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28417238" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bilateral Mastectomy as Overtreatment for Breast Cancer in Women Age Forty Years and Younger with Unilateral Operable Invasive Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784379" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457156" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110803" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Breast cancer surgery trends and outcomes: results from a National Department of Veterans Affairs study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047470" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30033183" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846780" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224779" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711183" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22695071" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204003" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545909" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Increasing incidence of bilateral mastectomies: the patient perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1419201" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The measurement of patient satisfaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944049" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cognitive dissonance, the placebo effect and the evaluation of surgical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551306" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243226" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156951" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Skin-sparing and nipple-sparing mastectomy: preoperative, intraoperative, and postoperative considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23865803" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sentinel lymph node biopsy for risk-reducing mastectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558796" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626202" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195327" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20853163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
